Positive Efficacy Findings Prompt Early Stop of Empagliflozin CKD Trial
The EMPA-KIDNEY study enrolled more than 6600 patients with CKD attributable to a wide range of underlying causes.
The EMPA-KIDNEY study enrolled more than 6600 patients with CKD attributable to a wide range of underlying causes.
The CRL stated that the application for bardoxolone could not be approved in its current form due to a lack of data supporting claims of slowing kidney function loss and reducing kidney failure progression.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
In a study of patients with stage 4 chronic kidney disease and poorly controlled blood pressure, chlorthalidone significantly decreased systolic blood pressure compared with placebo.
ALLN-346 is an investigational, first-in-class, nonabsorbed, orally-administered enzyme that breaks down urate in the gastrointestinal tract.
A recent review underscores the possible adverse effects of ketogenic diets, including increased risks for heart disease, cancer, diabetes, and kidney stones.
High variability in body mass index is associated with an increased risk for death, requiring kidney replacement therapy, myocardial infarction, and stroke, investigators concluded.
The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 clinical studies.
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Cardiovascular events are the leading cause of death among patients with chronic kidney disease, and metabolic acidosis in this population is underdiagnosed.